Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Person-centered intervention response in primary progressive aphasia: A secondary analysis of the Communication Bridge-2 randomized clinical trial.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026
Same author

Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Criterion and convergent validity of plasma biomarkers in early-onset Alzheimer's disease: Initial findings from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Associations between greenspace and memory: Evidence from the COMPASS cohort in Chicago.

Environmental research·2026
Same author

Psychometric criteria for superior cognitive performance in very old adults.

Journal of Alzheimer's disease : JAD·2026

Related Experiment Video

Updated: Jul 12, 2026

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

An update on primary progressive aphasia.

Emily Rogalski1, Marsel Mesulam

  • 1Cognitive Neurology and Alzheimer's Disease Center and Department of Neurology, Northwestern University, 320 E. Superior Street, Searle Building 11-453, Chicago, IL 60657, USA. rogalski@northwestern.edu

Current Neurology and Neuroscience Reports
|September 4, 2007
PubMed
Summary

Primary progressive aphasia (PPA) is a neurodegenerative brain disorder causing language decline. Recent research advances our understanding of PPA

More Related Videos

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Published on: February 21, 2011

Related Experiment Videos

Last Updated: Jul 12, 2026

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Published on: February 21, 2011

Area of Science:

  • Neurodegenerative diseases
  • Neurology
  • Linguistics

Background:

  • Primary progressive aphasia (PPA) is a neurodegenerative syndrome.
  • Characterized by progressive language dissolution with initial cognitive sparing.
  • Significant advancements in understanding PPA's clinical, imaging, genetic, and neuropathological aspects.

Purpose of the Study:

  • To review current clinical criteria for diagnosing PPA.
  • To highlight recent research progress in the field of PPA.

Main Methods:

  • Review of clinical diagnostic criteria for PPA.
  • Synthesis of recent research findings in PPA.

Main Results:

  • Established clinical criteria aid in PPA diagnosis.
  • Ongoing research is expanding knowledge on PPA's characteristics, imaging, genetics, and neuropathology.

Conclusions:

  • Accurate diagnosis of PPA relies on established clinical criteria.
  • Continued research is crucial for advancing the understanding and management of PPA.